Table 2.
Effects of pranlukast on the primary and secondary outcomes during the 1 st year
| Pranlukast N/total (%) | Placebo N/total (%) | RR *1 (95% CI *2 ) | RD *3 (95%CI *2 ) | P value | |
|---|---|---|---|---|---|
| Primary outcome*4 | 10/36 (28) | 14/39 (36) | 0.77 (0.39 to 1.52) | −0.08 (−0.29 to 0.13) | 0.45 |
| Secondary outcomes | |||||
| Major attack | 2/34 (6) | 2/38 (5) | 1.12 (0.17 to 7.51) | 0.01 (−0.10 to 0.11) | 0.91 |
| Moderate attack | 1/34 (3) | 4/38 (11) | 0.28 (0.03 to 2.38) | −0.08 (−0.19 to 0.04) | 0.21 |
| Mild attack | 8/34 (24) | 9/38 (24) | 0.99 (0.43 to 2.28) | −0.00 (−0.21 to 0.16) | 0.82 |
| Rescue medication use | |||||
| Rapid-acting inhaled β2-agonist | 12/36 (33) | 16/39 (41) | 0.81 (0.45 to 1.47) | −0.08 (−0.29 to 0.14) | 0.49 |
| Systemic glucocorticosteroid | 3/36 (0.8) | 1/39 (0.3) | 3.25 (0.35 to 29.8) | 0.06 (−0.05 to 0.16) | 0.27 |
| Inhaled glucocorticosteroid | 1/36 (0.3) | 1/39 (0.3) | 1.08 (0.07 to 16.7) | 0.00 (−0.07 to 0.08) | 0.95 |
*1RR: Relative risk, *2RD: 95%CI: 95% confidence interval, *3Risk difference, *4The primary outcome was defined as an increased frequency of wheezing: episodes of wheezing more than once per month, which continued for 3 months.